This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs
by Kanishka Das
ATAI is pursuing rapid-acting mental health treatments with key late-stage catalysts ahead, but its outlook still hinges on clinical execution and pipeline progress.
ATAINegative Net Change CMPSNegative Net Change GHRSNegative Net Change
biotechs
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
by Ahan Chakraborty
TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.
TNGXPositive Net Change RVMDPositive Net Change ERASNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026
by Kanishka Das
ATAI enters a catalyst-heavy 2026 as BPL-003 advances toward phase III, with upcoming pipeline milestones set to shape the clinical-stage biotech's outlook.
ATAINegative Net Change CMPSNegative Net Change GHRSNegative Net Change
biotechs
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
by Ahan Chakraborty
Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.
TNGXPositive Net Change RVMDPositive Net Change ERASNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Vertex Gets FDA Nod for Expanded Use of Casgevy in SCD & TDT
by Zacks Equity Research
VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in both inherited blood disorders.
VRTXNegative Net Change CRSPNegative Net Change LQDAPositive Net Change IMCRNegative Net Change
biotechs
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
by Ahan Chakraborty
Tango Therapeutics enters a pivotal phase as vopimetostat drives its investment case, with 2026 clinical updates set to test its focused oncology pipeline.
TNGXPositive Net Change RVMDPositive Net Change ERASNegative Net Change
biotechnology biotechs medical pharmaceuticals
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare
by Zacks Equity Research
Pacira gains a reimbursement boost as UnitedHealthcare separately covers Exparel in outpatient care, expanding access to non-opioid postsurgical pain treatment.
PCRXNegative Net Change AMRNPositive Net Change LQDAPositive Net Change IMCRNegative Net Change
biotechs
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
by Zacks Equity Research
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
CPRXPositive Net Change PTCTPositive Net Change LQDAPositive Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
by Zacks Equity Research
KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.
KYMRNegative Net Change SNYNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
by Zacks Equity Research
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.
VRDNNegative Net Change AMRNPositive Net Change LQDAPositive Net Change IMCRNegative Net Change
biotechs